Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients

Sunitinib is a tyrosine kinase inhibitor (TKI) used in treatment of metastatic renal cell carcinoma (mRCC), gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. One of the most common side effects related to sunitinib is hypothyroidism. Recent trials suggest correlation between the...

Descripción completa

Detalles Bibliográficos
Autores principales: Buda-Nowak, Anna, Kucharz, Jakub, Dumnicka, Paulina, Kuzniewski, Marek, Herman, Roman Maria, Zygulska, Aneta L., Kusnierz-Cabala, Beata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366170/
https://www.ncbi.nlm.nih.gov/pubmed/28343336
http://dx.doi.org/10.1007/s12032-017-0928-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366170/
https://www.ncbi.nlm.nih.gov/pubmed/28343336
http://dx.doi.org/10.1007/s12032-017-0928-z

Ejemplares similares